ECF506-d5

CAT: 0804-HY-112096SSize: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-112096SSize:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
ECF506-d5 (NXP900-d5) is deuterated labeled eCF506 (HY-112096) . eCF506 is a highly potent and orally active YES1/SRC kinase inhibitor with an IC50 of 0.47 nM. eCF506 locks its target into its native “closed” conformation, thereby inhibiting both kinase activity and complex formation with protein partners. eCF506 can be used for the study of esophageal squamous cancer and breast cancer[1][2][3].
Product Name Alternative
NXP900-d5
UNSPSC
12352005
Target
Isotope-Labeled Compounds; Src
Type
Isotope-Labeled Compounds
Related Pathways
Others; Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Solubility
10 mM in DMSO
Smiles
[2H]C1(CN(CC([2H])(C1(N(C)C)[2H])[2H])CCN2N=C(C(C2=NC=N3)=C3N)C4=CC=C(C(OC)=C4)NC(OC(C)(C)C)=O)[2H]
Molecular Formula
C26H33D5N8O3
Molecular Weight
515.66
References & Citations
[1]Fraser C, et al. Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase. J Med Chem. 2016 May 26;59 (10) :4697-710.|[2]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.|[3]Authors: Sweta Dash, et al. Preclinical efficacy of NXP900, a YES1/SRC kinase inhibitor in esophageal squamous cancer models. Journal of Clinical Oncology. Volume 41, Number 16_suppl.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Popular Products